Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $283.35M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
Merck USD 27.73B 786M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026